This is a working overview of immunomodulatory peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-13. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
A microprotein (miP) is a small protein of about 100–150 amino acids or fewer encoded from a small open reading frame (sORF), also known as sORF-encoded protein (SEP). They are a class of protein with a single protein domain. They are related to multidomain proteins. Microproteins regulate larger multidomain proteins at the post-translational level. Microproteins are analogous to microRNAs (miRNAs) and heterodimerize with their targets causing dominant and negative effects. In animals and plants, microproteins influence many biological processes. Because of their dominant effects on their targets, microproteins are currently under study for use in biotechnology. There are several methods for microprotein study, such as ribosome profiling, mass spectrometry, and genetic screening. In humans, they are associated with genetic diseases and cancers, and are called peptideins.
Central nervous system: headache (7%), dizziness (2%) Respiratory: upper respiratory tract infection (2%), cough (1%) Gastrointestinal: abdominal pain (5%), diarrhea (4%), nausea (4%), vomiting (3%), flatulence (3%), acid regurgitation (2%), constipation (2%) Neuromuscular and skeletal: back pain (1%), weakness (1%) Dermatologic: rash (2%) Other concerns related to adverse effects are:
15 July – Six members of the environmental protest group, Climate Camp Scotland, are arrested after the group occupies the Ineos gas power station at Grangemouth oil refinery. 16 July – A pod of 55 pilot whales dies after becoming stranded at Traigh Mhor beach at North Tolsta on the Isle of Lewis. 19 July – Police launch an operation to remove climate change protestors from Grangemouth Refinery, making 11 arrests. 21 July – Police Scotland confirms that climate change protestors have ended their demonstrations at two oil refineries at Grangemouth and Clydebank. 22 July – Four climate change protestors are arrested at Grangemouth after chaining themselves to an old washing machine. 25 July Following a trial at the High Court in Glasgow, Connor Gibson, 20, is found guilty of the sexual assault and murder of his 16-year-old sister, Amber Gibson, in November 2021. Stephen Corrigan, unknown to the siblings, is convicted of concealing the body. The Scottish Government approves a £500m plan to expand Argyll's Hollow Mountain underground power station. 26 July – The Scottish COVID-19 Inquiry begins, with its opening hearing taking place in Dundee. 27 July – First Minister Humza Yousaf unveils a new Scottish Government paper on independence that includes plans for Scottish citizenship and passports. 28 July – Glasgow Life confirms it has cancelled the 2023 Bonfire Night event usually held on Glasgow Green and has no plans to hold any similar events in future.
== Career == After his PhD, Wüthrich continued postdoctoral research with Fallab for a short time before leaving to work at the University of California, Berkeley for two years from 1965 with Robert E. Connick. That was followed by a stint working with Robert G. Shulman at the Bell Telephone Laboratories in Murray Hill, New Jersey from 1967 to 1969. Wüthrich returned to Switzerland, to Zürich, in 1969, where he began his career there at the ETH Zürich, rising to Professor of Biophysics by 1980. He currently maintains a laboratory at the ETH Zürich, at The Scripps Research Institute, in La Jolla, California and at the iHuman Institute of ShanghaiTech University. He has also been a visiting professor at the University of Edinburgh (1997–2000), the Chinese University of Hong Kong (where he was an Honorary Professor) and Yonsei University. During his graduate studies Wüthrich started out working with electron paramagnetic resonance spectroscopy, and the subject of his PhD thesis was "the catalytic activity of copper compounds in autoxidation reactions". During his time as a postdoc in Berkeley he began working with the newly developed and related technique of nuclear magnetic resonance spectroscopy to study the hydration of metal complexes. When Wüthrich joined the Bell Labs, he was put in charge of one of the first superconducting NMR spectrometers, and started studying the structure and dynamics of proteins. He has pursued this line of research ever since. After returning to Switzerland, Wüthrich collaborated with, among others, Nobel laureate Richard R.
Sources: en.wikipedia.org
Pakistan and Bangladesh have experienced strained relations, particularly under the Awami League governments led by Sheikh Hasina, driven by her pro-India stance and historical grievances. Pakistan, a prominent member of the Organisation of Islamic Cooperation (OIC), prioritises maintaining cultural, political, social, and economic relations with Arab and other Muslim-majority nations in its foreign policy. In September 2025, Pakistan and Saudi Arabia signed a Strategic Mutual Defence Agreement under which any aggression against one country is considered an aggression against both, formalising a defensive commitment that also extends Pakistan's nuclear umbrella to Saudi Arabia.
== Adverse effects == Adverse effects of flunitrazepam include dependency, both physical and psychological; reduced sleep quality resulting in somnolence; and overdose, resulting in excessive sedation, impairment of balance and speech, respiratory depression or coma, and possibly death. Because of the latter, flunitrazepam is commonly used in suicide among the elderly. When used in late pregnancy, it might cause hypotonia of the fetus.
==== Negative ion formation ==== In negative-ion mode, the potential of the exit grid electrode can be set to negative potentials. Penning electrons undergo electron capture with atmospheric oxygen to produce O2−. The O2− will produce radical anions. Several reactions are possible, depending on the analyte.
== Interactions == Nicergoline is known to enhance the cardiac depressive effects of propranolol. At high dosages, it is advisable to seek one's physician's guidance if combining with potent vasodilators such as bromocriptine, Ginkgo biloba, picamilon, vinpocetine or xantinol nicotinate.
==== Distribution ==== The volume of distribution of suvorexant is approximately 49 L. It crosses the blood–brain barrier and distributes into the central nervous system. Suvorexant has high plasma protein binding (99.5%). It is bound to albumin and α1-acid glycoprotein (orosomucoid).
Sources: en.wikipedia.org
== Cellulose esters and ethers == The hydroxyl groups (−OH) of cellulose can be partially or fully reacted with various reagents to afford derivatives with useful properties like mainly cellulose esters and cellulose ethers (−OR). In principle, although not always in current industrial practice, cellulosic polymers are renewable resources. Ester derivatives include:
In another case, a man ingested 200 castor beans mixed with juice in a blender and survived. Victims often manifest nausea, diarrhea, fast heart rate, low blood pressure, and seizures persisting for up to a week. Blood, plasma, or urine ricin or ricinine concentrations may be measured to confirm diagnosis. The laboratory testing usually involves immunoassay or liquid chromatography-mass spectrometry.
==== Ohio ==== In 2008, Ohio's Department of Agriculture (ODA) banned the use of labeling in dairy products as rBST-free because it was deemed misleading to consumers. However, the International Dairy Foods Association and the Organic Trade Association claimed ODA's ban was a violation of the first amendment by not allowing consumers to decide whether they deem the milk was safe and filed suit against the bill. "The district court granted summary judgment in favor of Ohio, concluding that using 'rBST' as a label was inherently misleading because it implies a compositional difference between those products that are produced with rBST and those that are not."
=== Proto-gene model === This proto-gene model agrees with the preadaptation model about the importance of pervasive expression, and refers to the set of pervasively expressed sequences that do not meet all definitions of a gene as "proto-genes". In contrast to the preadaptation model, the proto-gene model, suggests newborn genes have features intermediate between old genes and non-genes. Specifically this model envisages a more gradual process under selection from non-genic to genic state, rejecting the binary classification of gene and non-gene. In an extension of the proto-gene model, it has been proposed that as proto-genes become more gene-like, their potential for adaptive change gives way to selected effects; thus, the predicted impact of mutations on fitness is dependent on the evolutionary status of the ORF. This notion is supported by the fact that overexpression of established ORFs in S. cerevisiae tends to be less beneficial (and more harmful) than does overexpression of emerging ORFs. Several features of ORFs correlate with ORF age as determined by phylostratigraphic analysis, with young ORFs having properties intermediate between old ORFs and non-genes; this has been taken as evidence in favor of the proto-gene model, in which proto-gene state is a continuum . This evidence has been criticized, because the same apparent trends are also expected under a model in which identity as a gene is a binary. Under this model, when each age group contains a different ratio of genes vs. non-genes, Simpson's paradox can generate correlations in the wrong direction.
== Signs and symptoms == Sun-sensitive rash with prominent poikiloderma and telangiectasias Juvenile cataracts Saddle nose Congenital bone defects, including short stature and radial ray anomalies such as absent thumbs Hair growth problems (absent eyelashes, eyebrows and/or hair) Hypogonadism has not been well documented Hypodontia Calcium problems (not documented in journals) Ear problems (not documented in journals but identified by patients in support groups) Produces osteosarcoma The skin is normal at birth. Between 3 and 6 months of age, the affected carrier develops poikiloderma on the cheeks. This characteristic "rash" that all RTS carriers have can develop on the arms, legs and buttocks. "Poikiloderma consists of areas of increased and decreased pigmentation, prominent blood vessels, and thinning of the skin."
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.